a public good project by the
Synthesis
Company
of California

© 2026

Yumiko Hirokawa | doi.page

0 works0 citations0 h-index

Yumiko Hirokawa

The University of Melbourne(AU)Walter and Eliza Hall Institute of Medical Research(AU)

Publications by Year

Research Areas

Cancer-related Molecular Pathways, Cancer Genomics and Diagnostics, Cancer Cells and Metastasis, Wnt/β-catenin signaling in development and cancer, Crystallization and Solubility Studies

Most-Cited Works

→ Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?(2019)207 cited
→ Wnt Signalling Pathway Parameters for Mammalian Cells(2012)132 cited
→ A Clue to the Therapy of Neurofibromatosis Type 2(2004)101 cited
→ Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells(2023)82 cited
→ Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance(2005)81 cited
→ Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration(2014)76 cited

→ Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element(2004)

70 cited

→ The K252a Derivatives, Inhibitors for the PAK/MLK Kinase Family, Selectively Block the Growth of HAS Transformants(2002)69 cited

→ PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S Transition(2004)64 cited

Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.(2001)